Ngaphandle kokuba ukutya kwakho kucebile kwi calcium, i-calcium kunye ne-vitamin D zongezwa ukuba zithole inzuzo enkulu kwi-Evista (Raloxifene).
NgokweSiseko seSizwe se-Osteoporosis, abadala abangama-50 nangaphezulu badinga i-1,200 mg ye-calcium kunye ne-800 ukuya ku-1 000 ye-vitamin D3 imihla ngemihla. Umthombo okhethiweyo we-calcium i-calcium-rich riches foods, njengeemveliso zobisi, i-tofu, imifuno ethile eluhlaza kunye nokutya okuqinisekisiwe nge- calcium .
Yintoni iVevista?
Ukholo luhlobo lomuthi ogunyazisiweyo obizwa ngokuba yi-modermator receptor modulator (SERM). Isetyenziselwa ukunyanga okanye ukuthintela i-osteoporosis kubafazi emva kokumisa umva.
Xa usuqeda ukuphuma kwimizi, umzimba wakho uvelisa i-estrogen encinane, leyo, kwabanye besifazane, inokubangela ukuba amathambo athathele kwaye athathaka. I-Evista isebenza ngokunceda ukwenza amathambo akho anamandla kwaye angenakukwazi ukuphula. Inceda ukuthintela i-osteoporosis ngokwakha ithambo kunye nokunqumla ithambo elingahle lenzeke emva kokuphuma kwesisu.
Ngaba Ubunzima Bwenqanda Umhlaza Webele?
Ngokutsho kwe-US Food and Drug Administration (i-FDA), ukuba une-osteoporosis okanye usemngciphekweni omkhulu we-cancer yombele, i-Evista ingasetyenziselwa ukunciphisa amathuba okufumana umdlavuza webele we-invasive .
Nangona u-Evista akayi kuwuphelisa ngokupheleleyo ingozi yokufumana umdlavuza webele, ugqirha wakho unokulinganisa amathuba akho ngokufumana ingxaki yakho, kubandakanywa neminyaka yakho, imbali yentsapho yengomdla webele (kumama, udade okanye intombi), kwaye imbali yeyiphi isifuba sebele , ngakumbi i-biopsy engavamile.
Wena kunye nogqirha wakho unokugqiba ukuba iingeniso zokuthatha u-Evista zingaphezulu kweengozi zonyango.
Ziziphi iingozi zokuthatha uVangeli?
Kwamanye amabhinqa, iimiphumo ezibi kakhulu zingenzeka xa zithatha i-Evista, kuquka i-clots yegazi kunye ne-stroke.
Ingozi eyongeziweyo yamacangca egazi kwimilenze (inzulu ye-vein thrombosis) kunye nemiphunga (ukumbumbana kwamagulane) kuye kwabikwa ngo-Evista.
Ukuba unayo okanye ube neengcambu zegazi kwimilenze yakho okanye emaphaphu, akufanele uthathe u-Evista. Ukuba kusekho ixesha elide (njengokuba uhleli ebudeni bemoto ende okanye uhambo lwenqwelo, okanye ulala embhedeni emva kokuhlinzwa) kunokunyusa ingozi yegazi.
Ukuba unesifo senhliziyo okanye usemngciphekweni wokuhlaselwa kwentliziyo, unokufumana umngcipheko wokufa ngenxa yesifo xa uthabatha u-Evista.
Ukuba okwangoku uthatha u-Evista, yeka ukuyithatha kwaye ubize ugqirha wakho ukuba unayo:
- Intlungu yomlenze okanye uvakalelo lomfudumalo emlenzeni wakho ophantsi (ithole)
- Ukuvuvukala kwemilenze, izandla, okanye iinyawo
- intlungu yesifuba, ukuphefumula okufutshane, okanye igazi xa ukhwehlela
- Utshintsho olukhawuleza embonweni wakho, njengokulahlekelwa kombono okanye umbono ophazamisekileyo
Ndingafumana phi ulwazi olungakumbi malunga no-Evista?
Ukuze ufunde kabanzi malunga ne-Evista, funda i-Evista nesikhokelo sonyango oza kufuneka unikezwe xa ugcwalisa umyalelo wakho wokuqala kunye naso sonke ixesha ufumana ukuzaliswa. Ukuba awufumani nesikhokelo sonyango, cela umfama wakho ukuba ashicilele enye yakho. Unokufumana kwakhona isikhokelo kwi-intanethi kwiwebhsayithi ye-Eli Lilly neNkampani ( PDF ).
Ukongeza kwizilumkiso malunga ne-Evista evela kwi-FDA, isikhokelo sonyango sikwazisa ngemiphumo emibi kunye nokusebenzisana kwezidakamizwa.
Ukuba unemibuzo malunga nokusebenzisa i-Evista, xela ugqirha wakho.
Ulwazi olungakumbi malunga ne-Osteoporosis:
- I-Osteoporosis Foundation (i-NOF) - i-website ye-NOF inikeza ulwazi olufanelekileyo kubathengi malunga nokuthintela nokunyangwa kwe-osteoporosis, kubandakanywa namacebiso okukhusela okukhusela ukukhusela iifractures.
- I-Osteoporosis - inzulu, ingxelo eboniswe nge-osteoporosis evela kwi-Health Encyclopedia.
Imithombo:
I-FDA ivumela iiNtsebenzo ezintsha kwi-Evista. FDA News Release. US Food and Drug Administration. http://www.fda.gov/cder/Offices/OODP/whatsnew/raloxifene.htm
Eyona nto: Izinto ezigqwesileyo zokuLawulwa kolwazi. I-label ye-FDA yeDrug yobisi. US Food and Drug Administration. http://www.fda.gov/cder/foi/label/2007/022042lbl.pdf